{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:17:05Z","timestamp":1786979825309,"version":"build-2736575974"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1007\/s00228-019-02664-7","type":"journal-article","created":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T07:25:16Z","timestamp":1554103516000},"page":"1089-1097","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Population pharmacokinetic analysis of vancomycin in pediatric continuous renal replacement therapy"],"prefix":"10.1007","volume":"75","author":[{"given":"Brady S.","family":"Moffett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flor","family":"Munoz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayse Akcan","family":"Arikan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,4,1]]},"reference":[{"key":"2664_CR1","doi-asserted-by":"publisher","first-page":"329","DOI":"10.5414\/CN106993","volume":"77","author":"FP Wilson","year":"2012","unstructured":"Wilson FP, Berns JS (2012) Vancomycin levels are frequently subtherapeutic during continuous venovenous hemodialysis (CVVHD). Clin Nephrol 77:329\u2013331","journal-title":"Clin Nephrol"},{"key":"2664_CR2","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.jsps.2014.08.005","volume":"23","author":"AS Omrani","year":"2015","unstructured":"Omrani AS, Mously A, Cabaluna MP, Kawas J, Albarrak MM, Alfahad WA (2015) Vancomycin therapy in critically ill patients on continuous renal replacement therapy; are we doing enough? Saudi Pharm J 23:327\u2013329","journal-title":"Saudi Pharm J"},{"key":"2664_CR3","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1097\/CCM.0000000000000317","volume":"42","author":"JA Jamal","year":"2014","unstructured":"Jamal JA, Udy AA, Lipman J, Roberts JA (2014) The impact of variation in renal replacement therapy settings on piperacillin, meropenem, and vancomycin drug clearance in the critically ill: an analysis of published literature and dosing regimens. Crit Care Med 42:1640\u20131650","journal-title":"Crit Care Med"},{"key":"2664_CR4","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1053\/ajkd.1998.v31.pm9631848","volume":"31","author":"MS Joy","year":"1998","unstructured":"Joy MS, Matzke GR, Frye RF, Palevsky PM (1998) Determinants of vancomycin clearance by continuous venovenous hemofiltration and continuous venovenous hemodialysis. Am J Kidney Dis 31:1019\u20131027","journal-title":"Am J Kidney Dis"},{"key":"2664_CR5","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1097\/CCM.0b013e318241e553","volume":"40","author":"DM Roberts","year":"2012","unstructured":"Roberts DM, Roberts JA, Roberts MS, Liu X, Nair P, Cole L, Lipman J, Bellomo R, RENAL Replacement Therapy Study Investigators (2012) Variability of antibiotic concentrations in critically ill patients receiving continuous renal replacement therapy: a multicentre pharmacokinetic study. Crit Care Med 40:1523\u20131528","journal-title":"Crit Care Med"},{"key":"2664_CR6","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1086\/444500","volume":"41","author":"RL Trotman","year":"2005","unstructured":"Trotman RL, Williamson JC, Shoemaker DM, Salzer WL (2005) Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy. Clin Infect Dis 41:1159\u20131166","journal-title":"Clin Infect Dis"},{"key":"2664_CR7","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1007\/s00134-002-1495-z","volume":"28","author":"S Uchino","year":"2002","unstructured":"Uchino S, Cole L, Morimatsu H, Goldsmith D, Bellomo R (2002) Clearance of vancomycin during high-volume haemofiltration: impact of pre-dilution. Intensive Care Med 28:1664\u20131667","journal-title":"Intensive Care Med"},{"key":"2664_CR8","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1007\/s001340051018","volume":"25","author":"FT Boereboom","year":"1999","unstructured":"Boereboom FT, Ververs FF, Blankestijn PJ, Savelkoul TJ, van Dijk A (1999) Vancomycin clearance during continuous venovenous haemofiltration in critically ill patients. Intensive Care Med 25:1100\u20131104","journal-title":"Intensive Care Med"},{"key":"2664_CR9","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ijantimicag.2011.04.010","volume":"38","author":"W Chaijamorn","year":"2011","unstructured":"Chaijamorn W, Jitsurong A, Wiwattanawongsa K, Wanakamanee U, Dandecha P (2011) Vancomycin clearance during continuous venovenous haemofiltration in critically ill patients. Int J Antimicrob Agents 38:152\u2013156","journal-title":"Int J Antimicrob Agents"},{"key":"2664_CR10","doi-asserted-by":"publisher","first-page":"65","DOI":"10.5507\/bp.2012.092","volume":"158","author":"N Petejova","year":"2014","unstructured":"Petejova N, Martinek A, Zahalkova J, Duricova J, Brozmannova H, Urbanek K, Grundmann M, Plasek J, Kacirova I (2014) Vancomycin pharmacokinetics during high-volume continuous venovenous hemofiltration in critically ill septic patients. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 158:65\u201372","journal-title":"Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub"},{"key":"2664_CR11","doi-asserted-by":"publisher","first-page":"e138","DOI":"10.1097\/PCC.0000000000000656","volume":"17","author":"JJ Cies","year":"2016","unstructured":"Cies JJ, Moore WS 2nd, Conley SB et al (2016) Continuous infusion vancomycin through the addition of vancomycin to the continuous renal replacement therapy solution in the PICU: a case series. Pediatr Crit Care Med 17:e138\u2013e145","journal-title":"Pediatr Crit Care Med"},{"key":"2664_CR12","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1146\/annurev.pharmtox.48.113006.094708","volume":"48","author":"BJ Anderson","year":"2008","unstructured":"Anderson BJ, Holford NH (2008) Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol 48:303\u2013332","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"2664_CR13","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2133\/dmpk.24.25","volume":"24","author":"BJ Anderson","year":"2009","unstructured":"Anderson BJ, Holford NH (2009) Mechanistic basis of using body size and maturation to predict clearance in humans. Drug Metab Pharmacokinet 24:25\u201336","journal-title":"Drug Metab Pharmacokinet"},{"key":"2664_CR14","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1136\/archdischild-2013-303720","volume":"98","author":"BJ Anderson","year":"2013","unstructured":"Anderson BJ, Holford NH (2013) Understanding dosing: children are small adults, neonates are immature children. Arch Dis Child 98:737\u2013744","journal-title":"Arch Dis Child"},{"key":"2664_CR15","doi-asserted-by":"publisher","first-page":"82","DOI":"10.2146\/ajhp080434","volume":"66","author":"M Rybak","year":"2009","unstructured":"Rybak M, Lomaestro B, Rotschafer JC, Moellering R Jr, Craig W, Billeter M, Dalovisio JR, Levine DP (2009) Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 66:82\u201398","journal-title":"Am J Health Syst Pharm"},{"key":"2664_CR16","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1007\/s40262-015-0277-z","volume":"54","author":"HS Al-Sallami","year":"2015","unstructured":"Al-Sallami HS, Goulding A, Grant A, Taylor R, Holford N, Duffull SB (2015) Prediction of fat-free mass in children. Clin Pharmacokinet 54:1169\u20131178","journal-title":"Clin Pharmacokinet"},{"key":"2664_CR17","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1001\/jama.2016.6361","volume":"315","author":"CL Ogden","year":"2016","unstructured":"Ogden CL, Carroll MD, Lawman HG, Fryar CD, Kruszon-Moran D, Kit BK, Flegal KM (2016) Trends in obesity prevalence among children and adolescents in the United States, 1988-1994 through 2013-2014. Jama 315:2292\u20132299","journal-title":"Jama"},{"key":"2664_CR18","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.1093\/jac\/dkt261","volume":"68","author":"M Beumier","year":"2013","unstructured":"Beumier M, Roberts JA, Kabtouri H, Hites M, Cotton F, Wolff F, Lipman J, Jacobs F, Vincent JL, Taccone FS (2013) A new regimen for continuous infusion of vancomycin during continuous renal replacement therapy. J Antimicrob Chemother 68:2859\u20132865","journal-title":"J Antimicrob Chemother"},{"key":"2664_CR19","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1111\/j.1365-2125.2004.02143.x","volume":"58","author":"ME DelDot","year":"2004","unstructured":"DelDot ME, Lipman J, Tett SE (2004) Vancomycin pharmacokinetics in critically ill patients receiving continuous venovenous haemodiafiltration. Br J Clin Pharmacol 58:259\u2013268","journal-title":"Br J Clin Pharmacol"},{"key":"2664_CR20","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.ijantimicag.2014.03.009","volume":"44","author":"L Escobar","year":"2014","unstructured":"Escobar L, Andresen M, Downey P, Gai MN, Regueira T, B\u00f3rquez T, Lipman J, Roberts JA (2014) Population pharmacokinetics and dose simulation of vancomycin in critically ill patients during high-volume haemofiltration. Int J Antimicrob Agents 44:163\u2013167","journal-title":"Int J Antimicrob Agents"},{"key":"2664_CR21","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1023\/A:1020909324909","volume":"29","author":"SL Beal","year":"2002","unstructured":"Beal SL (2002) Commentary on significance levels for covariate effects in NONMEM. J Pharmacokinet Pharmacodyn 29:403\u2013410 discussion 11-2","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"2664_CR22","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1007\/s11095-007-9361-x","volume":"24","author":"AC Hooker","year":"2007","unstructured":"Hooker AC, Staatz CE, Karlsson MO (2007) Conditional weighted residuals (CWRES): a model diagnostic for the FOCE method. Pharm Res 24:2187\u20132197","journal-title":"Pharm Res"},{"key":"2664_CR23","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/sj.clpt.6100241","volume":"82","author":"MO Karlsson","year":"2007","unstructured":"Karlsson MO, Savic RM (2007) Diagnosing model diagnostics. Clin Pharmacol Ther 82:17\u201320","journal-title":"Clin Pharmacol Ther"},{"key":"2664_CR24","doi-asserted-by":"publisher","first-page":"e155","DOI":"10.1097\/INF.0b013e318286378e","volume":"32","author":"J Le","year":"2013","unstructured":"Le J, Bradley JS, Murray W et al (2013) Improved vancomycin dosing in children using area under the curve exposure. Pediatr Infect Dis J 32:e155\u2013e163","journal-title":"Pediatr Infect Dis J"},{"key":"2664_CR25","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.ijantimicag.2013.01.018","volume":"41","author":"AA Udy","year":"2013","unstructured":"Udy AA, Covajes C, Taccone FS, Jacobs F, Vincent JL, Lipman J, Roberts JA (2013) Can population pharmacokinetic modelling guide vancomycin dosing during continuous renal replacement therapy in critically ill patients? Int J Antimicrob Agents 41:564\u2013568","journal-title":"Int J Antimicrob Agents"},{"key":"2664_CR26","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13054-015-0818-8","volume":"19","author":"DM Roberts","year":"2015","unstructured":"Roberts DM, Liu X, Roberts JA et al (2015) A multicenter study on the effect of continuous hemodiafiltration intensity on antibiotic pharmacokinetics. Crit Care (London, England) 19:84","journal-title":"Crit Care (London, England)"},{"key":"2664_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/11596390-000000000-00000","volume":"51","author":"A Marsot","year":"2012","unstructured":"Marsot A, Boulamery A, Bruguerolle B, Simon N (2012) Vancomycin: a review of population pharmacokinetic analyses. Clin Pharmacokinet 51:1\u201313","journal-title":"Clin Pharmacokinet"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-019-02664-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-019-02664-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-019-02664-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,30]],"date-time":"2020-03-30T19:08:05Z","timestamp":1585595285000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-019-02664-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,1]]},"references-count":27,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["2664"],"URL":"https:\/\/doi.org\/10.1007\/s00228-019-02664-7","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,1]]},"assertion":[{"value":"13 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Institutional review board approval from Baylor College of Medicine and affiliated institutions was obtained","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors are currently receiving NIH funding for a prospective population pharmacokinetic trial of vancomycin in pediatrics.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}